Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury
1 other identifier
observational
N/A
1 country
1
Brief Summary
We previously reported early measurement of urinary MDA might be a useful marker for the prediction of CDDP-induced renal damage in rat. The purpose of this clinical study is to test whether the changes of human urinary excretion of MDA, and can be used as early biomarker for the prediction of development of CDDP-induced ARF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2006
CompletedFirst Posted
Study publicly available on registry
April 4, 2006
CompletedNovember 7, 2006
April 1, 2005
April 3, 2006
November 6, 2006
Conditions
Eligibility Criteria
You may qualify if:
- Hospitalized patients have neck cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, 431-3192, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Takayuki Tsuji, MD
Hamamatsu University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- NATURAL HISTORY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 3, 2006
First Posted
April 4, 2006
Last Updated
November 7, 2006
Record last verified: 2005-04